Business
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictiban
About this update from Pharvaris N.v.
[{"type":"image","alt":"Pharvaris N.V.","displaySize":"","headline":null,"caption":"Pharvaris N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0efc0ce5210d066470f326abda980f7b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h4nfp3SK54x7BD1u8yD8kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/0efc0ce5210d066470f326abda980f7b","width":300,"height":44}},"lazy":false},{"type":"text","content":"ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX.","length":672,"tagName":"p"},{"type":"text","content":"“Evaluating Safety Margins of the Use of Deucrictibant Extended-Release Tablet in Combination with Deucrictibant Immediate-Release Capsule” assessed human exposures across the anticipated dosing scenarios and calculated the corresponding safety margins based on available clinical and nonclinical data. The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s) in the event of a breakthrough attack, while on prophylaxis, is supported by evidence of adequate safety margins.","length":560,"tagName":"p"},{"type":"text","content":"A recently published post-hoc analysis of the prophylaxis CHAPTER-1 study assessed the mean duration of breakthrough attacks, in both placebo and deucrictibant arms, that were treated with a single dose of icatibant, another bradykinin B2 receptor antagonist. The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treat...